Adopting the Evolving Management of HR+/HER2-mBC into Practice
Annenberg Center for Health Sciences
4 episodes
19 hours ago
Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.
All content for Adopting the Evolving Management of HR+/HER2-mBC into Practice is the property of Annenberg Center for Health Sciences and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.
Adopting the Evolving Management of HR+/HER2-mBC into Practice
Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.
